Document is current

Article History

Received: 5 September 2024

Accepted: 13 March 2026

First Online: 7 April 2026

Declarations

:

: The study protocol was reviewed and approved by the Clinical Research and Applied Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Approval No. [2022] 037). This committee, composed of multidisciplinary experts (including clinicians, methodologies, and lay representatives) independent from the investigators and sponsor, is responsible for the initial and continuing ethical review and oversight of the trial. The committee will receive annual progress reports and be notified of any serious adverse events or protocol modifications. The study will proceed only after obtaining written informed consent from all participants. Study procedures will strictly observe the ethical standards of the Declaration of Helsinki.Given the single-center design, relatively short duration, and the well-established safety profile of empagliflozin, a separate independent data monitoring committee was not established for this trial. Safety monitoring and data integrity are ensured through regular assessments by the investigators and the aforementioned ethics committee.After completion, we will publish the results in a peer-reviewed journal.

: Not applicable.

: We declare that we have no conflict of interest.